212 related articles for article (PubMed ID: 34132181)
1. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
[TBL] [Abstract][Full Text] [Related]
2. Nonviral siRNA delivery systems for pancreatic cancer therapy.
Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
5. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
Lu ZR; Laney VEA; Hall R; Ayat N
Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers.
Yaghmur A; Østergaard J; Mu H
Adv Drug Deliv Rev; 2023 Dec; 203():115136. PubMed ID: 37944644
[TBL] [Abstract][Full Text] [Related]
7. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
8. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
[TBL] [Abstract][Full Text] [Related]
10. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP
J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469
[TBL] [Abstract][Full Text] [Related]
11. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer.
Hasan W; Chu K; Gullapalli A; Dunn SS; Enlow EM; Luft JC; Tian S; Napier ME; Pohlhaus PD; Rolland JP; DeSimone JM
Nano Lett; 2012 Jan; 12(1):287-92. PubMed ID: 22165988
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Treatment of Lung Cancer: Nanoparticle-based Drug and siRNA Delivery Systems.
Gencer A; Duraloglu C; Ozbay S; Ciftci TT; Yabanoglu-Ciftci S; Arica B
Curr Drug Deliv; 2021; 18(2):103-120. PubMed ID: 32748745
[TBL] [Abstract][Full Text] [Related]
14. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
16. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
17. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment.
Ahmed R; Amreddy N; Babu A; Munshi A; Ramesh R
Methods Mol Biol; 2019; 1974():265-290. PubMed ID: 31099010
[TBL] [Abstract][Full Text] [Related]
19. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Rahme K; Guo J; Holmes JD
Methods Mol Biol; 2019; 1974():291-301. PubMed ID: 31099011
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.
Lin Q; Jin CS; Huang H; Ding L; Zhang Z; Chen J; Zheng G
Small; 2014 Aug; 10(15):3072-82. PubMed ID: 24706435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]